Free Trial
NASDAQ:ZLAB

Zai Lab Q1 2025 Earnings Report

Zai Lab logo
$31.69 -0.15 (-0.47%)
As of 04:00 PM Eastern

Zai Lab EPS Results

Actual EPS
N/A
Consensus EPS
-$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Zai Lab Revenue Results

Actual Revenue
N/A
Expected Revenue
$118.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zai Lab Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Zai Lab Earnings Headlines

Zai Lab presents data from studies evaluating two oncology therapies
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).
Cantor Fitzgerald Reduces Earnings Estimates for Zai Lab
Zai Lab announces China NMPA acceptance of repotrectinib sNDA
See More Zai Lab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zai Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zai Lab and other key companies, straight to your email.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

View Zai Lab Profile

More Earnings Resources from MarketBeat